Anti-class II antibodies, but not cytotoxic T-lymphocyte antigen 4-immunoglobulin hybrid molecules, prevent rejection of major histocompatibility complex class II-negative myeloma in T-cell receptor-transgenic mice

Scandinavian Journal of Immunology

Volumn 60, Issue 1, 2004, Pages 143-152

  Dembic, Z ^a   Hofgaard, P O ^a   Omholt, H ^a   Bogen, B ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCLONAL ANTIBODY; T LYMPHOCYTE ANTIGEN; T LYMPHOCYTE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; DNA RECOMBINATION; MOUSE; MOUSE STRAIN; MYELOMA; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TRANSGENIC MOUSE; TUMOR GROWTH; TUMOR REJECTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION; CELL DIVISION; CROSSES, GENETIC; FLOW CYTOMETRY; HISTOCOMPATIBILITY ANTIGENS CLASS II; IMMUNOGLOBULIN IDIOTYPES; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; NEOPLASMS, EXPERIMENTAL; PLASMACYTOMA; RECEPTORS, ANTIGEN, T-CELL; SURVIVAL ANALYSIS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 3242701580     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0300-9475.2004.01435.x     Document Type: Article

References (41)

1. + T cell responses in antitumor immunity. Curr Opin Immunol 1998;10:588-94.
2. Toes RE, Ossendorp F, Offringa R, Melief CJ. CD4 T cells and their role in antitumor immune responses. J Exp Med 1999;189:753-6 [comment].
3. Pardoll DM. Spinning molecular immunology into successful immunotherapy. Nat Rev Immunol 2002;2:227-38.
4. + T cells in tumor resistance against major histocompatibility complex class II molecule negative plasmacytoma cells. Cell Immunol 1993;148:177-88.
5. Chaux P, Vantomme V, Stroobant V et al. Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes. J Exp Med 1999;189:767-78 [see comments].
6. Manici S, Sturniolo T, Imro MA et al. Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11. J Exp Med 1999;189:871-6 [see comments].
7. + T cells and immunosurveillance of B-cell tumors. Proc Natl Acad Sci USA 1994;91:5700-4.
8. Dembic Z, Rottingen JA, Dellacasagrande J, Schenck K, Bogen B. Phagocytic dendritic cells from myelomas activate tumor-specific T cells at a single cell level. Blood 2001;97:2808-14.
9. + T cells confer idiotype-specific tumor resistance in the absence of antibodies. Eur J Immunol 1995;25:3079-86.
10. + T cells. Proc Natl Acad Sci USA 2000;97:2697-702.
11. Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat Rev Immunol 2002;2:116-26.
12. Lynch RG, Graff RJ, Sirisinha S, Simms ES, Eisen HN. Myeloma proteins as tumor-specific transplantation antigens. Proc Natl Acad Sci USA 1972;69:1540-4.
13. Stevenson FK, George AJ, Glennie MJ. Anti-idiotypic therapy of leukemias and lymphomas. Chem Immunol 1990;48:126-66.
14. Levy R, Miller RA. Therapy of lymphoma directed at idiotypes. J Natl Cancer Inst Monogr 1990;10:61-8.
15. + T cells against B-cell lymphoma in the absence of anti-idiotypic antibodies. Blood 2003;102:605-12.
16. - T cell line to murine anti-alpha (1→3) dextran antibody. Cell Immunol 1996;174:180-9.
17. Kwak LW, Taub DD, Duffey PL et al. Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet 1995;345:1016-20.
18. Eisen HN, Simms ES, Potter M. Mouse myeloma proteins with antihapten antibody activity. The protein produced by plasma cell tumor MOPC-315. Biochemistry 1968;7:4126-34.
19. Bogen B, Malissen B, Haas W. Idiotope-specific T cell clones that recognize syngeneic immunoglobulin fragments in the context of class II molecules. Eur J Immunol 1986;16:1373-8.
20. Bogen B, Lambris JD. Minimum length of an idiotypic peptide and a model for its binding to a major histocompatibility complex class II molecule. EMBO J 1989;8:1947-52.
21. Muhlethaler-Mottet A, Otten LA, Steimle V, Mach B. Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA. EMBO J 1997;16:2851-60.
22. Bogen B, Gleditsch L, Weiss S, Dembic Z. Weak positive selection of transgenic T cell receptor-bearing thymocytes: importance of major histocompatibility complex class II, T cell receptor and CD4 surface molecule densities. Eur J Immunol 1992;22:703-9.
23. Munthe LA, Sollien A, Dembic Z, Bogen B. Preferential positive selection of T lymphocytes which express two different TCR alpha chains, an endogenous and a transgenic. Scand J Immunol 1995;42:651-61.
24. Dellacasagrande J, Schreurs OJ, Hofgaard PO et al. Liver metastasis of cancer facilitated by chemokine receptor CCR6. Scand J Immunol 2003;57:534-44.
25. Epstein SL, Ozato K, Bluestone JA, Sachs DH. Idiotypes of anti-Ia antibodies. I. Expression of the 14-4-4S idiotype in humoral immune responses. J Exp Med 1981;154:397-409.
26. Gajewski TF, Fallarino F, Uyttenhove C, Boon T. Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization. J Immunol 1996;156:2909-17.
27. Granucci F, Girolomoni G, Lutz MB et al. Modulation of cytokine expression in mouse dendritic cell clones. Eur J Immunol 1994;24:2522-6.
28. Chambers CA, Allison JP. Costimulatory regulation of T cell function. Curr Opin Cell Biol 1999;11:203-10.
29. Chen L, Ashe S, Brady WA et al. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1992;71:1093-102.
30. Huang AY, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 1994;264:961-5.
31. Huang AY, Bruce AT, Pardoll DM, Levitsky HI. Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo? J Exp Med 1996;183:769-76.
32. Linsley PS, Wallace PM, Johnson J et al. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science 1992;257:792-5.
33. Lenschow DJ, Zeng Y, Thistlethwaite JR et al. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA41g. Science 1992;257:789-92.
34. Chen L, McGowan P, Ashe S et al. Tumor immunogeniciry determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med 1994;179:523-32.
35. Chaux P, Martin MS, Martin F. T-cell co-stimulation by the CD28 ligand B7 is involved in the immune response leading to rejection of a spontaneously regressive tumor. Int J Cancer 1996;66:244-8.
36. Zhan Y, Corbett AJ, Brady JL, Sutherland RM, Lew AM. CD4 help-independent induction of cytotoxic CD8 cells to allogeneic P815 tumor cells is absolutely dependent on costimulation. J Immunol 2000;165:3612-9.
37. + T cell responses by ICOS/B7h costimulation. J Immunol 2001;167:132-9.
38. Liu X, Bai XF, Wen J et al. B7H costimulates clonal expansion of, and cognate destruction of tumor cells by, CD8(+) T lymphocytes in vivo. J Exp Med 2001;194:1339-48.
39. Zuberek K, Ling V, Wu P et al. Comparable in vivo efficacy of CD28/B7, ICOS/GL50, and ICOS/GL50B costimulatory pathways in murine tumor models: IFNgamma-dependent enhancement of CTL priming, effector functions, and tumor specific memory CTL. Cell Immunol 2003;225:53-63.
40. Liu X, Gao JX, Wen J et al. B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanism. J Exp Med 2003;197:1721-30.
41. Staveley-O'Carroll K, Sotomayor E, Montgomery J et al. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc Natl Acad Sci USA 1998;95:1178-83.